SCHEMBL25529258

SCHEMBL25529258

Cc1c(-c2ccco2)c(=O)c(C(=O)O)c2n1CCOC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.36
POLB P06746 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CTDSP1 Q9GZU7 2/20 0.36
ALDH1A1 P00352 3/20 0.35
RAB9A P51151 2/20 0.35
CYP1A2 P05177 1/20 0.35
ALOX5 P09917 1/20 0.34
PTGS1 P23219 1/20 0.34
PRKDC P78527 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
PKM P14618 2/20 0.33
HPGD P15428 1/20 0.33
KCNK3 O14649 3/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
RECQL P46063 1/20 0.32
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30174235 0.90 ALDH1A1 (0.34) L3MBTL1POLBTDP1CTDSP1ALDH1A1
SCHEMBL25529263 0.80 PIK3C3 (0.32) KCNK3KDM4E
SCHEMBL25529260 0.79 SMN1; SMN2 (0.36) ALDH1A1RAB9ACYP1A2PRKDCSMN1; SMN2
SCHEMBL25529249 0.77 PRKDC (0.35) ALOX5PTGS1PRKDCKCNK3KMT2A
SCHEMBL27218043 0.75 HDAC3 (0.31) KDM4E
SCHEMBL25529106 0.75 L3MBTL1 (0.44) L3MBTL1POLBTDP1CTDSP1ALDH1A1
SCHEMBL25229526 0.74 ALOX5 (0.42) POLBALDH1A1RAB9ACYP1A2ALOX5
SCHEMBL25529262 0.74 GRIN2B (0.33) ALDH1A1PKMKCNK3KMT2AKDM4E
SCHEMBL27218052 0.74 PSMB5 (0.31)
SCHEMBL30174219 0.70 CSNK1E (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
CN-115605478-A Compounds and methods of use 埃克塞里艾克西斯公司(US) 2023-01-13 CN disclosed
EP-4110779-A1 COMPOUNDS AND METHODS OF USE Exelixis, Inc. (US) 2023-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX L3MBTL1 3091/4885POLB 1012/4885TDP1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.